Discovery Biology Division studies diseases and pathogens, from which researchers establish disease models and assays for drug screening. Additionally, target identification and studies for the mechanism of action (MoA) are conducted for the candidates identified from screening.

• Viral Immunology Lab.
• Zoonotic Virus Lab.

Translational Research Division evaluates the drug efficacy of thousands of compounds through the cell- and image-based screening operated in the BSL-2 and BSL-3 laboratories and identifies novel candidates. The identified candidates are further developed to have more drug-like properties by SAR, toxicity and lead optimization studies and their in-vivo efficacy is evaluated in animal experiments.

• Antibacterial Resistance Lab.
• Advanced Biomedical Research Lab.

The Research Resource Center (RRC) of Institut Pasteur Korea is a core research facility that promotes fundamental virus research by providing access to BL-3, ABL-3, and Biobank facilities necessary for high-risk infectious disease research to external researchers. The RRC enhances national capabilities for infectious disease research and fosters synergies through collaborative research efforts.

• Biobank

The drug candidates are transferred for subsequent development including (pre-) clinical trials. Institut Pasteur Korea works closely in collaboration with the pharmaceutical industry, bio venture companies, academia and hospitals to enable its research technology and output to be utilized in helping the patients in need.

• Fostering Collaboration
• Research & Technology Service

IPK employs dynamic robotic platforms for high-throughput screening of chemical libraries and RNAi collections. Our fully-automated robotic platforms are located in BSL-2 and BSL-3 laboratories suitable for most pathogens and biological research.

• Core Technology Platform
• Major R&D Infrastructure